KR970702255A - 벤즈아미드 화합물 및 그의 약제학적 용도(benzamide compounds and pharmaceutical use thereof) - Google Patents

벤즈아미드 화합물 및 그의 약제학적 용도(benzamide compounds and pharmaceutical use thereof)

Info

Publication number
KR970702255A
KR970702255A KR1019960705864A KR19960705864A KR970702255A KR 970702255 A KR970702255 A KR 970702255A KR 1019960705864 A KR1019960705864 A KR 1019960705864A KR 19960705864 A KR19960705864 A KR 19960705864A KR 970702255 A KR970702255 A KR 970702255A
Authority
KR
South Korea
Prior art keywords
hydrogen
alkyl
pyridin
benzamide
aminoethyl
Prior art date
Application number
KR1019960705864A
Other languages
English (en)
Other versions
KR100311438B1 (ko
Inventor
마사후미 아리따
다다마사 사이또
마사노리 미노구찌
게이지 야마가미
히로유끼 사또
Original Assignee
고야 마사시
요시또미 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고야 마사시, 요시또미 세이야꾸 가부시끼가이샤 filed Critical 고야 마사시
Publication of KR970702255A publication Critical patent/KR970702255A/ko
Application granted granted Critical
Publication of KR100311438B1 publication Critical patent/KR100311438B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

하기 화학식(1)의 벤즈아미드 화합물
(식 중, 각 기호는 명세서에서 정의한 바와 같다), 그의 이성체 및 약제학적으로 허용가능한 그의 산부가염, 약제학적 조성물은 이 화합물 및 약제학적으로 허용가능한 첨가제의 치료적 유효량을 포함하며, 이 화합물은 고혈압 치료제, 협심증 치료제, 천식 치료제, 신장 및 말초 순환 장해 치료제 및 대뇌 현관 경련 저해제를 포함한다.
본 발명의 화합물은 장기 지속성 신장 및 말초 순환 개선 작용 뿐 아니라 강한 평활근 이완 작용을 가지며 종래의 칼슘 길항제와 같이 저혈압 작용 및 대뇌, 관상 현관 확장 작용을 나타낸다. 칼슘 길항제와는 달리, 이것은 경구 투여되어 여러 길항제에 의해 야기되는 현관 수축을 억제하며, 프로필락시스 및 관상, 대뇌, 신장 및 말초 현관에서의 순환 장해의 치료용의 강력하고 장기 작용성인 시약, 고혈압, 협심증 및 신장 및 말초 순환 장해의 치료제, 대뇌 현관 경련의 저해제 등으로서 유용하다. 또한, 본 발명의 화합물은 천식 치료제로서 유용하다.

Description

벤즈아미드 화합물 및 그의 약제학적 용도(BENZAMIDE COMPOUNDS AND PHARMACEUTICAL USE THEREOF)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 화학식(1)의 벤즈아미드 화합물, 그의 이성체 및 약제학적으로 허용가능한 그의 산부가염.
    [식중, R은 수소, 알킬, 또는 시클로알킬, 시클로알킬알킬, 페닐 또는 임의로는 고리상에 치환체를 갖는 아르알킬, 또는 화학식(2)의 기
    [식중, R6은 수소, 알킬 또는 식; -NR8R9(식중, 동일 또는 상이한 R8및 R9은 각각 수소, 알킬, 아르알킬 또는 페닐이다)이며, R7은 수소, 알킬, 아르알킬, 페닐, 니트로 또는 시아노이거나, R6및 R7은 결합하여 임의로는 산소 원자, 황 원자 또는 고리내에 부가적으로 임의로 치환된 질소 원자를 갖는 헤테로사이클을 형성한다]이며; R1은 수소, 알킬 또는 시클로알킬, 시클로알킬알킬, 페닐 또는 고리상에 치환체를 갖는 아르알킬이거나; R 및 R1은 인접한 질소 원자와 결합하여 산소 원자, 황 원자 또는 부가적으로 고리내에 임의로 치환된 질소원자를 갖는 헤테로사이클을 형성하며; 동일 또는 상이한 R2및 R3은 각각 수소, 알킬, 아르알킬, 할로겐, 니트로, 아미노, 알킬아미노, 아실아이노, 히드록시, 알콕시, 아르알킬옥시, 시아노, 아실, 메르캅토, 알킬티오, 아르알킬티오, 카르복시, 알콕시카르보닐, 카르바모일, 알킬카르바모일 또는 아지드이며; R4은 수소 또는 알킬이며, R5은 질소를 갖는 임의로 치환된 헤테로사이클이며; A는 화학식(3)
    (식중, 동일 또는 상이한 R10및 R11은 각각 수소, 알킬, 할로알킬, 아르알킬, 히드록시알킬, 카르복시 또는 알콕시카르보닐이거나, R10및 R11은 결합하여 시클로알킬을 형성하며, 1, m 및 n은 각각 0 또는 1 내지 3의 정 수이다)이다].
  2. 제1항에 있어서, 화학식 1에서 R, R1, R2, R3, R4, R5및 A중 하나 이상이 하기를 만족하는 것을 특징으로 하는 벤즈아미드 화합물, 그의 이성체 및 약제학적으로 허용가능한 그의 산부가염; R은 수소, 알킬, 또는 임의로는 고리상에 치환체를 갖는 아르알킬, 또는 화학식(2a)의 기
    {식 중, R6a은 수소 또는 식: -NR8aR9a(식 중, 동일 또는 상이한 R8a및 R9a은 각각 수소, 알킬 또는 아르알킬이다)이며, R7a은 수소, 알킬, 아르알킬 또는 페닐이거나, R6a및 R7a은 결합하여 임의로는 산소 원자, 황 원자 또는 고리내에 부가적으로 임의로 치환된 질소 원자를 갖는 헤테로사이클을 형성한다이며; R1은 수소, 알킬 또는 시클로알킬, 시클로알킬알킬, 페닐 또는 고리상에 치환체를 임의로 갖는 아르알킬이거나; R 및 R1은 인접한 질소 원자와 결합하여 산소 원자, 황 원자 또는 부가적으로 고리내에 임의로 치환된 질소원자를 갖는 헤테로사이클을 형성하며; 동일 또는 상이한 R2및 R3은 각각 수소, 알킬, 할로겐, 니트로, 아미노, 히드록시, 알콕시, 아르알킬옥시, 시아노, 아실, 카르복시, 알콕시카르보닐, 카르바모닐, 카르바모일 또는 아지드이며; R4은 수소 또는 알킬이며, R5은 질소를 갖는 임의로 치환된 헤테로사이클이며; A는 화학식(3a)
    (식중, 동일 또는 상이한 R10a및 R11a은 각각 수소, 알킬, 할로알킬, 히드록시알킬, 카르복시 또는 알콕시카르보닐이거나, R10a및 R11a은 결합하여 시클로알길을 형성하며, l, m 및 n은 각각 0 또는 1 내지 3의 정수이다)
    이다].
  3. 제1항에 있어서, 화학식 1에서 R, R1, R2, R3, R4, R5및 A중 하나 이상이 하기를 만족하는 것을 특징으로 하는 벤즈아미드 화합물, 그의 이성체 및 약제학적으로 허용가능한 그의 산부가염; R은 수소, 알킬 또는 화학식 (2b)의 기
    {식 중, R6b은 수소 또는 식: -NR8bR9b(식 중, 동일 또는 상이한 R8b및 R9b은 각각 수소, 또는 알킬이다)이며, R7b은 수소, 또는 알킬이거나, R6b및 R7b은 결합하여 임의로는 고리에 부가적으로 임의로 치환된 질소 원자를 갖는 헤테로사이클을 형성한다 이며; R1은 수소 또는 알킬이거나; R 및 R1은 인접한 질소 원자와 결합하여 임의로는 부가적으로 고리내에 임의로 치환된 질소원자를 갖는 헤테로사이클을 형성하며; 동일 또는 상이한 R2및 R3은 각각 수소, 할로겐, 니트로, 히드록시, 아르알킬옥시, 시아노, 카르복시, 알콕시카르보닐, 카르바모일 또는 아지드이며; R4은 수소이며, R5은 임의로 치환된 피리딘, lH-피롤로[2,3-b]피리딘 또는 1H-피라졸로[3,4-b]피리딘으로부터 유도되는 기이며; A는 화학식(3b)
    (식중, 동일 또는 상이한 R10b및 R11b은 각각 수소, 알킬, 히드록시알킬, 또는 카르복시이거나, R10a및 R11b은 결합하여 시클로알킬을 형성하며, l, m 및 n은 각각 0 또는 1 내지 3의 정수이며, m1은 0 또는 1이다)이다].
  4. 제1항에 있어서, 화학식(1)의 화합물로 하기로 구성된 군으로부터 선택한 것임을 특징으로 하는 벤즈아미드 화합물, 그의 이성체 및 약제학적으로 허용가능간 그의 산부가염.;
    (R)-N-(4-피리딘)-4-(1-아미노에틸)벤즈아미드, (R)-N-(4-피리딜) -4-(1-아미노에틸)-3-니트로벤즈아미드, (R)-N-(4-피리딜)-4-(l-아미노에틸)-3-클로로벤즈아미드, (R)-N-(4-피리필)-4-(1-아미노에틸)-2-니트로벤즈아미드, (R)-N-(4-피리딜)-4-(1-아미노에틸)-2-클로로벤즈아미드, (R)-N-(lH-피롤로[2,3-b]피리딘-4-일)-4-(l-아미노에틸)벤즈아미드, (R)-N-(lH-피롤로[2,3-b]피리딘-4-일)-4-(1-아미노에틸)-3-니트로벤즈아미드, (R)-N-(lH-피롤로[2,3-b]피리딘-4-일)-4-(1-아미노에틸)-3-아지드벤즈아미드, (R)-N-(3-이오드-lH-피롤로[2,3-b]피리딘-4-일)-4-(1-아미노에틸)-3-아지드벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노에틸)벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노에틸)-3-니트로벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노에틸)-2-니트로벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노에틸)-3-아지드벤즈아미드, (R)-N-[4-피리딜)-4-[]-구아니디노에틸)벤즈아미드, N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-구아니디노메틸벤즈아미드, (R)-N-(1H-피라졸로[3,4-b]피리딘-4-일)-4-(1-구아니디노에틸)벤즈아미드, N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-구아니디노메틸-3-니트로벤즈아미드, (R)-N-(lH)-피라졸로[3,4-b]피리딘-4-일)-4-(l-구아니디노에틸)-3-니트로벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-구아니디노에틸)-2-니트로벤즈아미드, (R)-N-(lH-피롤로[2,3-b]피리딘-4-일)-4-(1-구아니디노에틸)벤즈아미드, (R)-N-(lH-피롤로[2,3-b]피리딘-4-일)-4-(1-(3-프로필구아니디노)-에틸)벤즈아미드, (R)-N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노에틸)-3-시아노벤즈아미드, N-(lH-피라졸로[3,4-b]피리딘-4-일)-4-(1-아미노-2-히드록시에틸)벤즈아미드 및 (R)-N-(3-이오도-lH-피롤로[2,3-b]피리딘-4-일)-4-(1-아미노에틸)벤즈아미드.
  5. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염, 및 약제학적으로 허용가능한 첨가제의 치료적 유효량을 포함하는 약제학적 조성물.
  6. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염을 포함하는 고혈압 치료제.
  7. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염을 포함하는 협심증 치료제.
  8. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염을 포함하는 천식 치료제.
  9. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염을 포함하는 신장 및 말초 순환 장해 치료제.
  10. 제1항의 벤즈아미드 화합물, 그의 이성체 또는 약제학적으로 허용가능한 그의 산부가염을 포함하는 대뇌 혈관 경련 저해제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705864A 1994-04-18 1995-04-17 벤즈아미드화합물및그의약제학적용도 KR100311438B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP94-78280 1994-04-18
JP7828094 1994-04-18
PCT/JP1995/000747 WO1995028387A1 (fr) 1994-04-18 1995-04-17 Compose benzamide et utilisation medicale dudit compose

Publications (2)

Publication Number Publication Date
KR970702255A true KR970702255A (ko) 1997-05-13
KR100311438B1 KR100311438B1 (ko) 2002-06-20

Family

ID=13657559

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705864A KR100311438B1 (ko) 1994-04-18 1995-04-17 벤즈아미드화합물및그의약제학적용도

Country Status (8)

Country Link
US (2) US5958944A (ko)
EP (3) EP1195372A1 (ko)
KR (1) KR100311438B1 (ko)
AT (1) ATE255093T1 (ko)
CA (1) CA2188164C (ko)
DE (1) DE69532195T2 (ko)
ES (2) ES2208678T3 (ko)
WO (1) WO1995028387A1 (ko)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4783774B2 (ja) * 1996-08-12 2011-09-28 田辺三菱製薬株式会社 Ｒｈｏキナーゼ阻害剤を含有する医薬
EP0956865B2 (en) * 1996-08-12 2010-08-18 Mitsubishi Tanabe Pharma Corporation MEDICINES COMPRISING Rho KINASE INHIBITOR
EP1459743B9 (en) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1174150A4 (en) * 1999-04-22 2004-06-16 Mitsubishi Pharma Corp PREVENTIVE / HEALING AGENT FOR ANGIOSTENOSIS
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
JP2003506388A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP2003531856A (ja) * 2000-05-02 2003-10-28 スミスクライン・ビーチャム・コーポレイション リン酸輸送阻害剤
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
CA2422560A1 (en) * 2000-09-20 2002-03-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-amino-quinazolines
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
MY142915A (en) * 2001-03-23 2011-01-31 Bayer Healthcare Llc Rho-kinase inhibitors
JP4329003B2 (ja) * 2001-03-23 2009-09-09 バイエル コーポレイション Ｒｈｏキナーゼ阻害剤
CA2443918C (en) * 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
WO2003059913A1 (en) * 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
JP4469179B2 (ja) * 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
CA2473910C (en) * 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
DE60324104D1 (en) * 2002-01-30 2008-11-27 Amgen Inc Arylsulfonamidobenzylverbindungen
WO2003063796A2 (en) * 2002-01-30 2003-08-07 Tularik Inc. Heterocyclic arylsulfonamidobenzylic compounds
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
MXPA04012704A (es) 2002-06-19 2005-03-23 Schering Corp Agonistas de los receptores canabinoides.
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
CA2506464C (en) 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA06001566A (es) * 2003-08-12 2006-05-15 Amgen Inc Compuestos arilsulfonamidobencilicos.
WO2005062795A2 (en) 2003-12-19 2005-07-14 Plexxikon, Inc. Compounds and methods for development of ret modulators
GB0403635D0 (en) * 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
US7485654B2 (en) * 2004-06-03 2009-02-03 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
CN101287707A (zh) * 2005-10-13 2008-10-15 德福根有限公司 激酶抑制剂
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
KR20090057223A (ko) 2006-07-31 2009-06-04 센주 세이야꾸 가부시키가이샤 아미드 화합물을 함유하는 수성 액제
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008070823A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8088793B2 (en) 2007-08-15 2012-01-03 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
GB0914726D0 (en) * 2009-08-24 2009-09-30 Univ Manchester Kinase inhibitors
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2011080984A1 (en) 2009-12-29 2011-07-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US10908161B2 (en) 2013-07-30 2021-02-02 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US11624053B2 (en) 2013-11-27 2023-04-11 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP7008337B2 (ja) 2016-02-15 2022-02-10 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
WO2020045642A1 (ja) 2018-08-31 2020-03-05 学校法人同志社 眼細胞を保存または培養するための組成物および方法
EP3862424A4 (en) 2018-10-02 2022-06-29 The Doshisha Method and vessel for preserving corneal endothelial cells
KR20220146552A (ko) 2020-02-27 2022-11-01 교토후고리츠다이가쿠호진 인간 기능성 각막 내피 세포 및 그 응용

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971789A (en) * 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
DE2520896A1 (de) * 1975-05-10 1976-11-25 Basf Ag Azopigmente der beta-hydroxynaphthoesaeurereihe
ES438120A1 (es) * 1975-06-02 1977-02-01 Gallardo Antonio Sa Procedimiento para la preparacion de amidas aromaticas.
FI763021A (ko) * 1975-11-03 1977-05-04 Thomae Gmbh Dr K
ES456989A1 (es) 1977-03-18 1978-07-16 Lafarquim Procedimiento de obtencion de un derivado de 4-aminopiridinay sus sales.
IT1126509B (it) * 1979-12-07 1986-05-21 Medea Res Srl Benzimidi ad attivita' anestetica locale e antiaritmica,processo per la loro preparazione e composizioni farmaceutiche che le contengono
JPS57206662A (en) * 1981-06-15 1982-12-18 Chugai Pharmaceut Co Ltd Benzamide derivative
US4720500A (en) * 1985-07-11 1988-01-19 Rhone-Poulenc Sante N-1,8-naphthyridin-2-yl amides useful as immunostimulants
FR2592882B2 (fr) * 1986-01-16 1988-03-11 Rhone Poulenc Sante Nouveaux amides substitues, leur preparation et les medicaments qui les contiennent
JPS6229566A (ja) * 1985-07-30 1987-02-07 Taiyo Yakuhin Kogyo Kk 新規グアニジノメチル安息香酸誘導体
JPS6290657A (ja) * 1985-10-17 1987-04-25 Fuji Photo Film Co Ltd ２当量カプラ−単量体の製造方法
JPS62158252A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンベンズアミド誘導体
JPS62158253A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
JPS6368551A (ja) * 1986-09-10 1988-03-28 Shiseido Co Ltd Ｎ−〔２−ヒドロキシ−２−（４−ヒドロキシフエニル）エチル〕ベンズアミドおよび該化合物を有効成分とする循環器疾患治療剤および皮膚外用剤
JPS63126860A (ja) * 1986-11-17 1988-05-30 Nippon Haipotsukusu:Kk グアニジノメチル安息香酸誘導体
EP0278173B1 (en) * 1986-12-17 1993-11-03 Glaxo Group Limited Use of heterocyclic derivatives in the treatment of depressions
US4743610A (en) * 1987-03-16 1988-05-10 American Cyanamid Company N-[ω(3-pyridinyl)alkyl]benzamides, useful as thromboxane synthetase enzyme and/or cardioprotective agents
EP0303445A1 (en) * 1987-08-13 1989-02-15 Walton S.A. Clebopride transdermal patch
DE3804346A1 (de) * 1988-02-12 1989-08-24 Boehringer Mannheim Gmbh Tert.-butylphenyl-pyridyl-amide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US4948891A (en) * 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
WO1990005723A1 (en) * 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
WO1993005021A1 (en) * 1991-09-06 1993-03-18 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof

Also Published As

Publication number Publication date
EP1391454A1 (en) 2004-02-25
EP1195372A1 (en) 2002-04-10
US5958944A (en) 1999-09-28
US6156766A (en) 2000-12-05
EP0757038A1 (en) 1997-02-05
EP0757038A4 (en) 1997-08-06
EP0757038B1 (en) 2003-11-26
CA2188164A1 (en) 1995-10-26
CA2188164C (en) 2005-08-09
ES2388917T3 (es) 2012-10-19
ES2208678T3 (es) 2004-06-16
DE69532195T2 (de) 2004-09-02
ATE255093T1 (de) 2003-12-15
DE69532195D1 (de) 2004-01-08
WO1995028387A1 (fr) 1995-10-26
KR100311438B1 (ko) 2002-06-20
EP1391454B1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
KR970702255A (ko) 벤즈아미드 화합물 및 그의 약제학적 용도(benzamide compounds and pharmaceutical use thereof)
AR036597A1 (es) Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1
RU93058253A (ru) Соединения-антибиотики, способы их получения, промежуточные соединения, фармкомпозиция, способ лечения
JP2008526999A5 (ko)
CA2436846A1 (en) Thioether substituted imidazoquinolines
RU2005116254A (ru) Производные пиридопирролизина и пиридоиндолизина
CA2443918A1 (en) Visual function disorder improving agents containing rho kinase inhibitors
CY1112024T1 (el) Αναστολεις υποδοχεων adp αιμοπεταλιων
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
KR960705795A (ko) 항염증제로서의 이속사졸린 화합물(isoxazoline compounds as antinflammatiory agents)
CA2369560A1 (en) Agent for prophylaxis and treatment of liver disease
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
CA2437718A1 (en) Carboline derivatives
KR960007565A (ko) 약제로서의 치환된 4-페닐-6-아미노-니코틴산 유도체의 용도
DE69131759T2 (de) An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
AR002761A1 (es) Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo.
JP2004525183A5 (ko)
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
EE200000059A (et) Tetrahüdro-gamma-karboliinid
AR035465A1 (es) Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios
GB0310726D0 (en) Therapeutic agents
KR890001988A (ko) 치환된 알켄카복실산아미드 및 이의유도체
ATE342266T1 (de) 1-methylcarbapenemderivate
RU2004130284A (ru) Антипаразитарные производные артемизинина (эндопероксиды)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130903

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140901

Year of fee payment: 14

EXPY Expiration of term